Phase 2Recruiting
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Sponsored by Innovent Biologics (Suzhou) Co. Ltd.
About this study
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Enrolling at this location
University of California, San Francisco (UCSF)
San Francisco, California
I'm interestedThis study also enrolls at 8 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.